ORIC Pharmaceuticals, Inc.

DB:4TZ Stock Report

Market Cap: €644.8m

ORIC Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

ORIC Pharmaceuticals's earnings have been declining at an average annual rate of -19.1%, while the Biotechs industry saw earnings growing at 7.7% annually.

Key information

-19.1%

Earnings growth rate

45.6%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth raten/a
Return on equity-43.7%
Net Marginn/a
Last Earnings Update30 Sep 2024

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How ORIC Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:4TZ Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-12028107
30 Jun 240-1112798
31 Mar 240-1022688
31 Dec 230-1012685
30 Sep 230-932477
30 Jun 230-932469
31 Mar 230-902564
31 Dec 220-892562
30 Sep 220-912562
30 Jun 220-852560
31 Mar 220-852462
31 Dec 210-792257
30 Sep 210-842052
30 Jun 210-911848
31 Mar 210-811640
31 Dec 200-741336
30 Sep 200-541131
30 Jun 200-35928
31 Mar 200-30725
31 Dec 190-27623
31 Dec 180-21319

Quality Earnings: 4TZ is currently unprofitable.

Growing Profit Margin: 4TZ is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 4TZ is unprofitable, and losses have increased over the past 5 years at a rate of 19.1% per year.

Accelerating Growth: Unable to compare 4TZ's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 4TZ is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).


Return on Equity

High ROE: 4TZ has a negative Return on Equity (-43.75%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies